Diatomite is a natural porous
silica material of sedimentary origin. Due to its peculiar properties, it can be considered as a valid surrogate of synthetic porous
silica for nano-based
drug delivery. In this work, we exploit the potential of
diatomite nanoparticles (DNPs) for
drug delivery with the aim of developing a successful dual-biofunctionalization method by
polyethylene glycol (PEG) coverage and
cell-penetrating peptide (
CPP) bioconjugation, to improve the physicochemical and
biological properties of the particles, to enhance the intracellular uptake in
cancer cells, and to increase the biocompatibility of
3-aminopropyltriethoxysilane (
APT) modified-DNPs. DNPs-
APT-PEG-
CPP showed hemocompatibility for up to 200 μg mL(-1) after 48 h of incubation with erythrocytes, with a
hemolysis value of only 1.3%. The cytotoxicity of the modified-DNPs with a concentration up to 200 μg mL(-1) and incubation with MCF-7 and MDA-MB-231
breast cancer cells for 24 h, demonstrated that PEGylation and
CPP-bioconjugation can strongly reduce the cytotoxicity of DNPs-
APT. The cellular uptake of the modified-DNPs was also evaluated using the above mentioned
cancer cell lines, showing that the
CPP-bioconjugation can considerably increase the DNP cellular uptake. Moreover, the dual surface modification of DNPs improved both the loading of a poorly water-soluble anticancer
drug,
sorafenib, with a loading degree up to 22 wt%, and also enhanced the drug release profiles in aqueous solutions. Overall, this work demonstrates that the biofunctionalization of DNPs is a promising platform for
drug delivery applications in
cancer therapy as a result of its enhanced stability, biocompatibility, cellular uptake, and drug release profiles.